Download full-text


Available from: Mario Preti, Sep 27, 2015
10 Reads
  • Source
    • "The incidence of HPV-associated VIN, unlike that of vulvar carcinomas, has been increasing over the past 20 years, especially in women of reproductive age, with the highest frequency reported in women of 20–35 years old [7–9]. dVIN type and non-HPV-related vulvar SCC occur commonly in elderly women [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma are three relatively frequent vulvar lesions. Condyloma acuminatum is induced by low risk genotypes of human papillomavirus (HPV). Vulvar intraepithelial neoplasia (VIN) and squamous cell carcinoma have different etiopathogenic pathways and are related or not with high risk HPV types. The goal of this paper is to review the main pathological and clinical features of these lesions. A special attention has been paid also to epidemiological data, pathological classification, and clinical implications of these diseases.
    02/2014; 2014(1):480573. DOI:10.1155/2014/480573
  • Source
    • "Vulvar intraepithelial neoplasia (VIN) is a premalignant skin condition that often causes severe and long-lasting pruritus, pain and psychosexual dysfunction [1]. It can be classified into differentiated type VIN, which is associated with lichen sclerosus, and usual type VIN [2], which is caused by a persistent infection of high-risk human papillomavirus (hrHPV) [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently we reported on the efficacy of imiquimod for treating vulvar intraepithelial neoplasia (VIN) in a placebo-controlled, double-blinded randomized clinical trial (RCT). Four weeks after treatment, a complete response was observed in 35% of patients and a partial response in 46%. All complete responders remained disease-free at 12 months follow-up. In the current investigations, we assessed long-term follow-up at least 5 years after the initial RCT. Twenty-four of 26 imiquimod-treated patients who had participated in the initial RCT were seen for follow-up. Primary endpoint was durability of clinical response to imiquimod assessed by naked eye vulvar examination and histology. Long-term clinical response was correlated to lesion size before start of the initial RCT. Secondary endpoints were mental health, global quality of life, body image and sexual function in relation with long-term clinical response. Median follow-up period was 7.2 years (range 5.6-8.3 years). VIN recurred in one of nine complete responders. Of the initial partial responders, two became disease-free after additional imiquimod treatment. In the other partial responders, VIN recurred at least once after the initial RCT. In long-term complete responders, lesion size at study entry was smaller and these patients had a significantly better global quality of life at follow-up than patients with residual disease and/or recurrence after imiquimod treatment. In case of a complete response, imiquimod is effective in the long-term. Furthermore, patients with a long-term complete response had a significantly better global quality of life than patients who recurred after imiquimod treatment.
    Gynecologic Oncology 04/2011; 121(1):157-62. DOI:10.1016/j.ygyno.2010.12.340 · 3.77 Impact Factor
Show more